TNF expressed by tumor-associated macrophages, but not microglia, can eliminate glioma

International Journal of Oncology

Volumn 30, Issue 4, 2007, Pages 803-811

  Nakagawa, Jiro ^a   Saio, Masanao ^a   Tamakawa, Noriyuki ^a   Suwa, Tatsuhiko ^a   Frey, Alan B ^b   Nonaka, Kenichi ^a   Umemura, Naoki ^a   Imai, Hisashi ^a   Ouyang, Guan Feng ^a   Ohe, Naoyuki ^a   Yano, Hirohito ^a   Yoshimura, Sinichi ^a   Iwama, Toru ^a   Tsuyoshi, Takami ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Central nervous system; Interleukin 2 tumor immunity; Microglia; Tumor necrosis factor; Tumor associated macrophages

Indexed keywords

CD11B ANTIGEN; INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA;

ADENOCARCINOMA; ADOPTIVE IMMUNOTHERAPY; ANIMAL; ARTICLE; BRAIN TUMOR; C57BL MOUSE; CHEMISTRY; GLIOMA; IMMUNOLOGY; MACROPHAGE; MALE; METABOLISM; MICROGLIA; MOUSE; TRANSPLANTATION; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; ANTIGENS, CD11B; BRAIN NEOPLASMS; CELL LINE, TUMOR; GLIOMA; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICROGLIA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34247890112     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.30.4.803     Document Type: Article

References (26)

1. Lichtor T and Glick RP: Cytokine immuno-gene therapy for treatment of brain tumors. J Neurooncol 65: 247-259, 2003.
2. Glick RP, Lichtor T, de Zoeten E, Deshmukh P and Cohen EP: Prolongation of survival of mice with glioma treated with semi-allogeneic fibroblasts secreting interleukin-2. Neurosurgery 45: 867-874, 1999.
3. Wood GW, Holladay FP, Turner T, Wang YY and Chiga M: A pilot study of autologous cancer cell vaccination and cellular immunotherapy using anti-CD3 stimulated lymphocytes in patients with recurrent grade III/IV astrocytoma. J Neurooncol 48: 113-120, 2000.
4. Jeffes EW III, Beamer YB, Jacques S, et al: Therapy of recurrent high grade gliomas with surgery, and autologous mitogen activated IL-2 stimulated killer (MAK) lymphocytes: I. Enhancement of MAK lytic activity and cytokine production by PHA and clinical use of PHA. J Neurooncol 15: 141-155, 1993.
5. Merchant RE, Grant AJ, Merchant LH and Young HF: Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2. Cancer 62: 665-671, 1988.
6. Lewis CE and Pollard JW: Distinct role of macrophages in different tumor microenvironments. Cancer Res 66: 605-612, 2006.
7. Niedbala MJ: Cytokine regulation of endothelial cell extracellular proteolysis. Agents Actions Suppl 42: 179-193, 1993.
8. Ware CF, Van Arsdale S and Van Arsdale TL: Apoptosis mediated by the TNF-related cytokine and receptor families. J Cell Biochem 60: 47-55, 1996.
9. So T, Lee SW and Croft M: Tumor necrosis factor/tumor necrosis factor receptor family members that positively regulate immunity. Int J Hematol 83: 1-11, 2006.
10. Wallach D, Varfolomeev EE, Malinin NL, Goltsev YV, Kovalenko AV and Boldin MP: Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol 17: 331-367, 1999.
11. Saio M, Radoja S, Marino M and Frey AB: Tumor-infiltrating macrophages induce apoptosis in activated CD8(+) T cells by a mechanism requiring cell contact and mediated by both the cellassociated form of TNF and nitric oxide. J Immunol 167: 5583-5593, 2001.
12. Balkwill F and Mantovani A: Inflammation and cancer: back to Virchow? Lancet 357: 539-545, 2001.
13. Mantovani A, Bottazzi B, Colotta F, Sozzani S and Ruco L: The origin and function of tumor-associated macrophages. Immunol Today 13: 265-270, 1992.
14. Goerdt S and Orfanos CE: Other functions, other genes: alternative activation of antigen-presenting cells. Immunity 10: 137-142, 1999.
15. Mantovani A, Sozzani S, Locati M, Allavena P and Sica A: Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23: 549-555, 2002.
16. Sinha P, Clements VK and Ostrand-Rosenberg S: Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. Cancer Res 65: 11743-11751, 2005.
17. Biswas SK, Gangi L, Paul S, et al: A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood 107: 2112-2122, 2006.
18. Guillemin GJ, and Brew BJ: Microglia, macrophages, perivascular macrophages, and pericytes: a review of function and identification. J Leukoc Biol 75: 388-397, 2004.
19. Goddard S, Williams A, Morland C, Qin S, Gladue R, Hubscher SG and Adams DH: Differential expression of chemokines and chemokine receptors shapes the inflammatory response in rejecting human liver transplants. Transplantation 72: 1957-1967, 2001.
20. + T-cells. Glia 22: 348-359, 1998.
21. Sica A, Schioppa T, Mantovani A and Allavena P: Tumourassociated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer 42: 717-727, 2006.
22. Pace JL, Russell SW, Torres BA, Johnson HM and Gray PW: Recombinant mouse gamma interferon induces the priming step in macrophage activation for tumor cell killing. J Immunol 130: 2011-2013, 1983.
23. Young DA, Lowe LD and Clark SC: Comparison of the effects of IL-3, granulocyte-macrophage colony-stimulating factor, and macrophage colony-stimulating factor in supporting monocyte differentiation in culture. Analysis of macrophage antibody-dependent cellular cytotoxicity. J Immunol 145: 607-615, 1990.
24. Hori K, Ehrke MJ, Mace K, Maccubbin D, Doyle MJ, Otsuka Y and Mihich E: Effect of recombinant human tumor necrosis factor on the induction of murine macrophage tumoricidal activity. Cancer Res 47: 2793-2798, 1987.
25. Feinman R, Henriksen-DeStefano D, Tsujimoto M and Vilcek J: Tumor necrosis factor is an important mediator of tumor cell killing by human monocytes. J Immunol 138: 635-640, 1987.
26. Ouyang GF, Saio M, Suwa T, et al: Interleukin-2 augmented activation of tumor associated macrophage plays the main role in MHC class I in vivo induction in tumor cells that are MHC negative in vitro. Int J Oncol 28: 1201-1208, 2006.